Active substance
Sodium polystyrene sulfonate
- SFDA 1
- US FDA 18
- Health Canada 6
- US price lines 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SODANOR POWDER FOR ORAL/RECTAL SUSP. | 99.934 % | Powder for oral/rectal suspension · Oral, Rectal | 1 Jar | SAR 268.75 | NCE · Prescription | Alrai Pharmaceutical industry Co. (L.L.C) | Valid |
Indications — CHI Daman Drug Formulary
CHRONIC KIDNEY DISEASE-HYPERKALEMIA; CONSTIPATION; HYPERKALEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SPS | 15GM/60ML | suspension · oral, rectal | CMP PHARMA INC | Prescription | 8 Dec 1982 |
| SODIUM POLYSTYRENE SULFONATE | 454GM/BOT | powder · oral, rectal | CMP PHARMA INC | Prescription | 19 Jan 1989 |
| KIONEX | 454GM/BOT | powder · oral, rectal | ANI PHARMS | Prescription | 6 Feb 1998 |
| KIONEX | 15GM/60ML | suspension · oral, rectal | ANI PHARMS | Prescription | 17 Sep 2007 |
| KALEXATE | 454GM/BOT; 15GM/BOT | powder · oral, rectal | KVK TECH | Prescription | 30 Mar 2009 |
| SODIUM POLYSTYRENE SULFONATE | 453.6GM/BOT | powder · oral, rectal | UPSHER SMITH LABS | Prescription | 21 Dec 2011 |
| SODIUM POLYSTYRENE SULFONATE | 453.6GM/BOT | powder · oral, rectal | EPIC PHARMA LLC | Prescription | 19 Mar 2014 |
| SODIUM POLYSTYRENE SULFONATE | 454GM/BOT; 15GM/BOT | powder · oral, rectal | NUVO PHARMS INC | Prescription | 28 Nov 2014 |
| SODIUM POLYSTYRENE SULFONATE | 454GM/BOT | powder · oral, rectal | CHARTWELL RX | Prescription | 18 Feb 2016 |
| SODIUM POLYSTYRENE SULFONATE | 454GM/BOT | powder · oral, rectal | AJENAT PHARMS | Prescription | 23 Feb 2016 |
| SODIUM POLYSTYRENE SULFONATE | 15GM/60ML | suspension · oral, rectal | LYNE | Prescription | 10 Jun 2025 |
| KAYEXALATE | 453.6GM/BOT **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | powder · oral, rectal | CONCORDIA | Discontinued | 5 Jun 1958 |
| SODIUM POLYSTYRENE SULFONATE | 453.6GM/BOT | powder · oral, rectal | PAI HOLDINGS PHARM | Discontinued | 11 Sep 1984 |
| SODIUM POLYSTYRENE SULFONATE | 15GM/60ML | suspension · oral, rectal | HIKMA PHARMS | Discontinued | 17 Nov 1986 |
| SODIUM POLYSTYRENE SULFONATE | 454GM/BOT | powder · oral, rectal | CITRUSPHRMA | Discontinued | 3 Dec 2008 |
| SODIUM POLYSTYRENE SULFONATE | 15GM/60ML | suspension · oral, rectal | ANI PHARMS | Discontinued | 13 May 2011 |
| SODIUM POLYSTYRENE SULFONATE | 15GM/60ML | suspension · oral, rectal | ROXANE | Discontinued | |
| SODIUM POLYSTYRENE SULFONATE | 15GM/60ML | suspension · oral, rectal | MORTON GROVE | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| JAMP SODIUM POLYSTYRENE SULFONATE | 02497557 | 1 G / G | POWDER FOR SUSPENSION · ORAL; RECTAL | JAMP PHARMA CORPORATION |
| KAYEXALATE | 02026961 | 1 G / G | POWDER FOR SUSPENSION · ORAL; RECTAL | SANOFI-AVENTIS CANADA INC |
| ODAN-SODIUM POLYSTYRENE SULFONATE | 02473941 | 1 G / G | POWDER FOR SUSPENSION · RECTAL; ORAL | ODAN LABORATORIESLTD |
| ODAN-SODIUM POLYSTYRENE SULFONATE | 02473968 | 250 MG / ML | SUSPENSION · ORAL; RECTAL | ODAN LABORATORIESLTD |
| SOLYSTAT | 00755338 | 1 G / G | POWDER FOR SUSPENSION · ORAL; RECTAL | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
| SOLYSTAT | 00769541 | 250 MG / ML | SUSPENSION · ORAL | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | KIONEX 15 GM/60 ML SUSPENSION | $0.30564 | per ML | 23 Sep 2026 |
| US NADAC | SPS 15 GM/60 ML SUSPENSION | $0.43798 | per ML | 23 Sep 2026 |
| US NADAC | SPS 15 GM/60 ML SUSPENSION | $0.38512 | per ML | 22 Apr 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 28 Jul 2017 KAYEXALATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.